Megan Ken

Dr. Megan Ken

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2019 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
LGLaura R. Ganser
Laura R. Ganser
MKMegan Ken
Megan Ken
DHDaniel Herschlag
Daniel Herschlag
HAHashim M. Al-Hashimi
Hashim M. Al-Hashimi
RNAs fold into 3D structures that range from simple helical elements to complex tertiary structures and quaternary ribonucleoprotein assemblies. The functions of many regulatory RNAs depend on how their 3D structure changes in response to a diverse array of cellular conditions. In this Review, we examine how the structural characterization of RNA as dynamic ensembles of conformations, which form with different probabilities and at different timescales, is improving our understanding of RNA function in cells. We discuss the mechanisms of gene regulation by microRNAs, riboswitches, ribozymes, post-transcriptional RNA modifications and RNA-binding proteins, and how the cellular environment and processes such as liquid–liquid phase separation may affect RNA folding and activity. The emerging RNA-ensemble–function paradigm is changing our perspective and understanding of RNA regulation, from in vitro to in vivo and from descriptive to predictive.

4 May 2018 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
LGLaura R. Ganser
Laura R. Ganser
JLJanghyun Lee
Janghyun Lee
ARAtul Rangadurai
Atul Rangadurai
DMDawn K. Merriman
Dawn K. Merriman
MKMegan Ken
Megan Ken
HAHashim M. Al-Hashimi
Hashim M. Al-Hashimi
Dynamic ensembles hold great promise in advancing RNA-targeted drug discovery. Here we subjected the transactivation response element (TAR) RNA from human immunodeficiency virus type-1 to experimental high-throughput screening against ~100,000 drug-like small molecules. Results were augmented with 170 known TAR-binding molecules and used to generate sublibraries optimized for evaluating enrichment when virtually screening a dynamic ensemble of TAR determined by combining NMR spectroscopy data and molecular dynamics simulations. Ensemble-based virtual screening scores molecules with an area under the receiver operator characteristic curve of ~0.85–0.94 and with ~40–75% of all hits falling within the top 2% of scored molecules. The enrichment decreased significantly for ensembles generated from the same molecular dynamics simulations without input NMR data and for other control ensembles. The results demonstrate that experimentally determined RNA ensembles can significantly enrich libraries with true hits and that the degree of enrichment is dependent on the accuracy of the ensemble.

31 January 2017 in Epilepsia
Verified
Journal Article
Open access
PDF file
SMSarah B. Mulkey
Sarah B. Mulkey
BBBruria Ben‐Zeev
Bruria Ben‐Zeev
JNJoost Nicolai
Joost Nicolai
JCJohn L. Carroll
John L. Carroll
SGSabine Grønborg
Sabine Grønborg
MCMaria Roberta Cilio
Maria Roberta Cilio
Summary: Objective: To analyze whether KCNQ2 R201C and R201H variants, which show atypical gain‐of‐function electrophysiologic properties in vitro, have a distinct clinical presentation and outcome.Methods: Ten children with heterozygous, de novo KCNQ2 R201C or R201H variants were identified worldwide, using an institutional review board (IRB)–approved KCNQ2 patient registry and database. We reviewed medical records and, where possible, interviewed parents and treating physicians using a structured, detailed phenotype inventory focusing on the neonatal presentation and subsequent course.Results: Nine patients had encephalopathy from birth and presented with prominent startle‐like myoclonus, which could be triggered by sound or touch. In seven patients, electroencephalography (EEG) was performed in the neonatal period and showed a burst‐suppression pattern. However, myoclonus did not have an EEG correlate. In many patients the paroxysmal movements were misdiagnosed as seizures. Seven patients developed epileptic spasms in infancy. In all patients, EEG showed a slow background and multifocal epileptiform discharges later in life. Other prominent features included respiratory dysfunction (perinatal respiratory failure and/or chronic hypoventilation), hypomyelination, reduced brain volume, and profound developmental delay. One patient had a later onset, and sequencing indicated that a low abundance (~20%) R201C variant had arisen by postzygotic mosaicism.Significance: Heterozygous KCNQ2 R201C and R201H gain‐of‐function variants present with profound neonatal encephalopathy in the absence of neonatal seizures. Neonates present with nonepileptic myoclonus that is often misdiagnosed and treated as seizures. Prognosis is poor. This clinical presentation is distinct from the phenotype associated with loss‐of‐function variants, supporting the value of in vitro functional screening. These findings suggest that gain‐of‐function and loss‐of‐function variants need different targeted therapeutic approaches.

24 July 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAnn M. Guggisberg
Ann M. Guggisberg
JPJooyoung Park
Jooyoung Park
RERachel L. Edwards
Rachel L. Edwards
MKMegan Ken
Megan Ken
DHDana M. Hodge
Dana M. Hodge
AOAudrey R. Odom
Audrey R. Odom
Isoprenoid biosynthesis through the methylerythritol phosphate (MEP) pathway generates commercially important products and is a target for antimicrobial drug development. MEP pathway regulation is poorly understood in microorganisms. Here we employ a forward genetics approach to understand MEP pathway regulation in the malaria parasite, Plasmodium falciparum. The antimalarial fosmidomycin inhibits the MEP pathway enzyme deoxyxylulose 5-phosphate reductoisomerase (DXR). Fosmidomycin-resistant P. falciparum are enriched for changes in the PF3D7_1033400 locus (hereafter referred to as PfHAD1), encoding a homologue of haloacid dehalogenase (HAD)-like sugar phosphatases. We describe the structural basis for loss-of-function PfHAD1 alleles and find that PfHAD1 dephosphorylates a variety of sugar phosphates, including glycolytic intermediates. Loss of PfHAD1 is required for fosmidomycin resistance. Parasites lacking PfHAD1 have increased MEP pathway metabolites, particularly the DXR substrate, deoxyxylulose 5-phosphate. PfHAD1 therefore controls substrate availability to the MEP pathway. Because PfHAD1 has homologues in plants and bacteria, other HAD proteins may be MEP pathway regulators.

1 February 2013 in Eukaryotic Cell
Verified
Journal Article
Open access
PDF file
RHRuth Howe
Ruth Howe
MKMegan Ken
Megan Ken
JJJohn Jimah
John Jimah
DHDana Hodge
Dana Hodge
AOAudrey R. Odom
Audrey R. Odom
The antimalarial agent fosmidomycin is a validated inhibitor of the nonmevalonate isoprenoid biosynthesis (methylerythritol 4-phosphate [MEP]) pathway in the malaria parasite, Plasmodium falciparum . Since multiple classes of prenyltransferase inhibitors kill P. falciparum , we hypothesized that protein prenylation was one of the essential functions of this pathway. We found that MEP pathway inhibition with fosmidomycin reduces protein prenylation, confirming that de novo isoprenoid biosynthesis produces the isoprenyl substrates for protein prenylation. One important group of prenylated proteins is small GTPases, such as Rab family members, which mediate cellular vesicular trafficking. We have found that Rab5 proteins dramatically mislocalize upon fosmidomycin treatment, consistent with a loss of protein prenylation. Fosmidomycin treatment caused marked defects in food vacuolar morphology and integrity, consistent with a defect in Rab-mediated vesicular trafficking. These results provide insights to the biological functions of isoprenoids in malaria parasites and may assist the rational selection of secondary agents that will be useful in combination therapy with new isoprenoid biosynthesis inhibitors.

17 May 2023 in Nature
Verified
Journal Article
Closed access
PDF file
MKMegan Ken
Megan Ken
RRRohit Roy
Rohit Roy
AGAinan Geng
Ainan Geng
LGLaura R. Ganser
Laura R. Ganser
AMAkanksha Manghrani
Akanksha Manghrani
HAHashim M. Al-Hashimi
Hashim M. Al-Hashimi